Randomised Phase I/II trial assessing the safety and efficacy of radiolabelled anti-carcinoembryonic antigen I131KAb201 antibodies given intra-arterially or intravenously in patients with unresectable pancreatic adenocarcinoma

Table 2 Patient characteristics (randomised patients)

	Intra-venous (n = 9)	Intra-arterial (n = 10)	Total (n = 19)
Age, years
median ((25th, 75th centile) min, max	60 (59,60) 53–66	59 (55,63) 47–67	60 (57,63) 47–67
Karnofsky Performance Status
Score ≤ 80	3 (33%)	7 (70%)	10 (53%)
Score ≥ 90	6 (67%)	3 (30%)	9 (47%)
Stage
IVa	2 (22%)	6 (60%)	8 (42%)
IVb	7 (78%)	4 (40%)	11 (58%)
Previous treatment
	3 (33%)^φ	1 (10%)^ξ	4 (21%)
Time from diagnosis to randomisation, days
median ((25th, 75th centile)	84 (60,203)	37 (16,115)	77 (25,177)
min, max	27–316	2–256	2–316

^φ one patient each had received: gemcitabine plus oxaliplatin 6 cycles, gemcitabine 8 cycles and gemcitabine 7 cycles
^ξgemcitabine 3 cycles.

ISSN: 1471-2407